<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742404</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000612434</org_study_id>
    <secondary_id>ONCOTHER-X05272-DOXILMMY2010</secondary_id>
    <secondary_id>DVD study</secondary_id>
    <nct_id>NCT00742404</nct_id>
  </id_info>
  <brief_title>Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and&#xD;
      dexamethasone, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells&#xD;
      by blocking some of the enzymes needed for cell growth and by blocking blood flow to the&#xD;
      tumor. Giving bortezomib together with combination chemotherapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving doxorubicin hydrochloride liposome&#xD;
      together with bortezomib and dexamethasone works in treating patients with newly diagnosed&#xD;
      multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the response rate (i.e., complete response, very good partial response ,&#xD;
           partial response, and minimal response) in patients with newly diagnosed multiple&#xD;
           myeloma treated with pegylated liposomal doxorubicin hydrochloride, bortezomib, and&#xD;
           dexamethasone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  To determine the time to disease progression, time to response, duration of response,&#xD;
           progression-free survival, and overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 30-90&#xD;
      minutes, dexamethasone IV, and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every&#xD;
      28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and urine samples are collected at baseline and periodically during study for M-protein&#xD;
      analysis by electrophoresis and immunofixation.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum M-protein</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 24-hour urine M-protein</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma based on the following criteria:&#xD;
&#xD;
               -  Major criteria&#xD;
&#xD;
                    -  Plasmacytomas on tissue biopsy (1)&#xD;
&#xD;
                    -  Bone marrow plasmacytosis (&gt; 30% plasma cells) (2)&#xD;
&#xD;
                    -  Monoclonal immunoglobulin spike on serum electrophoresis IgG &gt; 3.5 g/dL or&#xD;
                       IgA &gt; 2.0 g/dL and kappa or lambda light chain excretion &gt; 1 g/day on&#xD;
                       24-hour urine protein electrophoresis (3)&#xD;
&#xD;
               -  Minor criteria&#xD;
&#xD;
                    -  Bone marrow plasmacytosis (10% to 30% plasma cells) (a)&#xD;
&#xD;
                    -  Monoclonal immunoglobulin present but of lesser magnitude than given under&#xD;
                       major criteria (b)&#xD;
&#xD;
                    -  Lytic bone lesions (c)&#xD;
&#xD;
                    -  Normal IgM &lt; 50 mg/dL, IgA &lt; 100 mg/dL, or IgG &lt; 600 mg/dL (d)&#xD;
&#xD;
          -  Meets 1 of the following sets of diagnostic criteria:&#xD;
&#xD;
               -  Any two of the major criteria&#xD;
&#xD;
               -  Major criteria 1 and minor criteria b, c, and d&#xD;
&#xD;
               -  Major criteria 3 and minor criteria a or c&#xD;
&#xD;
               -  Minor criteria a, b, c, OR a, b, d&#xD;
&#xD;
          -  Measurable disease, defined as a monoclonal immunoglobulin spike on serum&#xD;
             electrophoresis ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike ≥ 200 mg/24&#xD;
             hours, or evidence of lytic bone disease&#xD;
&#xD;
               -  No nonmeasurable disease (i.e., non-secretory or oligosecretory multiple myeloma)&#xD;
&#xD;
          -  Symptomatic, newly diagnosed, and previously untreated multiple myeloma&#xD;
&#xD;
          -  No POEMS syndrome (i.e., plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein [M-protein], and skin changes)&#xD;
&#xD;
          -  No plasma cell leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^³ (≥ 1,000/mm^³ if bone marrow is extensively infiltrated)&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^³ (≥ 50,000/mm^³ if bone marrow is extensively infiltrated)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum bilirubin ≤ 2.0 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min OR creatinine &gt; 10 mL/min and &lt; 30 mL/min for&#xD;
             patients with significant myelomatous involvement of the kidneys&#xD;
&#xD;
          -  Serum potassium ≥ lower limit of normal (LLN)&#xD;
&#xD;
          -  Serum sodium ≥ LLN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 within past 14 days&#xD;
&#xD;
          -  No impaired cardiac function or clinically significant cardiac disease, including any&#xD;
             one of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class II-IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Clinically significant pericardial disease&#xD;
&#xD;
               -  Severe uncontrolled ventricular arrhythmias&#xD;
&#xD;
               -  LVEF below normal by ECHO or MUGA scan&#xD;
&#xD;
               -  ECG evidence of acute ischemia or active conduction system abnormalities&#xD;
&#xD;
                    -  Screening ECG abnormality must be documented by the investigator as not&#xD;
                       medically relevant&#xD;
&#xD;
          -  No severe hypercalcemia (i.e., serum calcium ≥ 14 mg/dL [3.5 mmol/L])&#xD;
&#xD;
          -  No poorly controlled hypertension, diabetes mellitus, or other serious medical or&#xD;
             psychiatric illness that could preclude study treatment&#xD;
&#xD;
          -  No known HIV positivity or hepatitis B or C positivity&#xD;
&#xD;
               -  Baseline testing for HIV and hepatitis B or C is not required&#xD;
&#xD;
          -  No history of allergic reaction attributable to compounds of similar chemical or&#xD;
             biological composition to doxorubicin, bortezomib, boron, or mannitol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior or concurrent anti-myeloma therapy except steroids&#xD;
&#xD;
               -  Prior prednisone for ≤ 4 days at a total of 400 mg (or an equivalent potency of&#xD;
                  another steroid) allowed&#xD;
&#xD;
               -  No concurrent corticosteroids (≥ 10 mg prednisone/day or equivalent) other than&#xD;
                  dexamethasone&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
               -  Prior kyphoplasty with oncotherapeutic drugs allowed at the investigator's&#xD;
                  discretion&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy, antibody therapy, or radiotherapy&#xD;
&#xD;
          -  More than 14 days since other prior and no other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R. Berenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Clinical Research Center, Incorporated</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309-0633</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Pacific Oncology and Hematology Associates, Incorporated - Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Care Medical Associates - San Gabriel</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Cancer Care</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center at Roseville Medical Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Hematology Oncology Medical Group at Cancer Center of Santa Barbara</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James R. Berenson MD, Incorporated</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <name_title>Regulatory Affairs Associate</name_title>
    <organization>Oncotherapeutics</organization>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

